Roles of intercellular cell adhesion molecule-1 (ICAM-1) in colorectal cancer: expression, functions, prognosis, tumorigenesis, polymorphisms and therapeutic implications

Zhiyuan Qiu, Yan Wang, Zhao Zhang, Rong Qin, Yong Peng, Weifeng Tang, Yan Xi, Guangyu Tian, Yeqing ZhangFrontiers in Oncology 2022 · DOI

This review paper, published in Frontiers in Oncology, provides a comprehensive synthesis of the multifaceted role of Intercellular Adhesion Molecule-1 (ICAM-1) in colorectal cancer (CRC). It explores how this single glycoprotein acts as a "double-edged sword"—alternately aiding the immune system and facilitating tumor progression depending on its form and the surrounding cellular context.

TL;DR

ICAM-1 is a critical regulator of colorectal cancer progression, where its membrane-bound form often promotes anti-tumor immunity while its soluble form (sICAM-1) serves as a marker for metastasis and poor prognosis. The paper highlights how genetic polymorphisms and complex regulatory networks make ICAM-1 both a promising biomarker and a challenging therapeutic target.

What Problem Does This Paper Address?

Colorectal cancer remains a leading cause of cancer-related mortality globally. To improve outcomes, researchers need a deeper understanding of the molecular mechanisms driving tumorigenesis, metastasis, and immune evasion.

ICAM-1 (also known as CD54) has long been known as a "glue" that helps cells stick together or to the extracellular matrix. However, its role in CRC has been controversial: some studies suggest it helps the body fight cancer, while others link it to advanced disease. This paper addresses this ambiguity by reviewing the protein's structure, its regulation by cytokines and microRNAs, the impact of genetic variations (SNPs), and its potential as a target for modern therapies like CAR-T cells.

Methods

As a review article, the authors did not conduct new laboratory experiments. Instead, they performed a systematic synthesis of existing literature, citing 98 peer-reviewed studies. They categorized findings into thematic areas:

  • Structural Biology: Analyzing the five Ig-like domains of ICAM-1 and their ligand interactions (e.g., LFA-1, Mac-1).
  • Clinical Correlation: Aggregating data from multiple patient cohorts to compare membrane-bound vs. soluble ICAM-1 levels.
  • Genetic Analysis: Reviewing meta-analyses of Single Nucleotide Polymorphisms (SNPs) across different ethnicities.
  • Regulatory Mapping: Tracing the signaling pathways (NF-κB, JAK-STAT3) and microRNAs that control ICAM-1 expression.

Datasets

The paper summarizes data from various clinical studies and meta-analyses rather than introducing a new dataset. Notable references include:

  • Table 1: A comparison of sICAM-1 levels in patients vs. controls across six different clinical studies, showing significantly elevated levels in CRC patients (e.g., one study showed 743.7 ng/mL in patients vs. 345.7 ng/mL in controls).
  • Table 2: A summary of ICAM-1 SNP (specifically rs5498, rs3093030, and rs179969) associations with CRC risk in Greek, Chinese, Caucasian, and Malaysian populations.

Key Insights and Ideas

  • The "Dual Role" Paradox: Membrane-bound ICAM-1 on tumor cells is generally a positive prognostic factor because it facilitates the adhesion of cytotoxic T-lymphocytes (CTLs), allowing the immune system to recognize and kill the tumor.
  • The Soluble Decoy: ICAM-1 can be "shed" from the cell surface via proteolytic cleavage, becoming soluble ICAM-1 (sICAM-1). High levels of sICAM-1 in the blood correlate with advanced tumor stage and liver metastasis. It is thought that sICAM-1 acts as a decoy, binding to T-cells and preventing them from reaching the actual tumor.
  • Genetic Influence: The rs5498 polymorphism is a major focus. The "KK" genotype is associated with higher ICAM-1 expression and better tumor differentiation in some populations, but its effect on overall cancer risk varies significantly by ethnicity.
  • MicroRNA Regulation: The paper identifies a sophisticated "brake" system where various microRNAs (like miR-221, miR-339, and miR-141) bind to the ICAM-1 mRNA to suppress its translation, potentially aiding tumor immune evasion.

Key Results

  • Prognostic Value: Increased membrane-bound ICAM-1 is linked to favorable prognosis and inhibited tumor growth in several cited studies (e.g., Maeda K et al., Tachimori A et al.).
  • Metastasis Marker: sICAM-1 is a robust biomarker for malignancy; levels decrease significantly after curative surgery, suggesting its utility in monitoring treatment success.
  • Therapeutic Potential: Preclinical studies show that targeting ICAM-1 with CAR-T cell therapy or using it as a component of CpG-ODN vaccinations can successfully trigger tumor infiltration by immune cells and inhibit growth.

Limitations and Future Work

  • Context Dependency: The primary limitation is the lack of a "unified theory" for ICAM-1; its function is highly dependent on the tumor microenvironment and whether the protein is membrane-bound or soluble.
  • Ethnic Variability: Genetic findings are inconsistent across different global populations, meaning a "one-size-fits-all" genetic screening for CRC risk via ICAM-1 SNPs is currently unfeasible.
  • Clinical Translation: While anti-tumor therapies targeting ICAM-1 (like CAR-T) show promise in the lab, the authors note that clinical trials are still needed to ensure these treatments don't cause off-target inflammatory damage to healthy tissues that also express ICAM-1.

Summary updated

Abstract

Colorectal cancer (CRC) is a major global health problem and one of the major causes of cancer-related death worldwide. It is very important to understand the pathogenesis of CRC for early diagnosis, prevention strategies and identification of new therapeutic targets. Intercellular adhesion molecule-1 (ICAM-1, CD54) displays an important role in the the pathogenesis of CRC. It is a cell surface glycoprotein of the immunoglobulin (Ig) superfamily and plays an essential role in cell-cell, cell-extracellular matrix interaction, cell signaling and immune process. It is also expressed by tumor cells and modulates their functions, including apoptosis, cell motility, invasion and angiogenesis. The interaction between ICAM-1 and its ligand may facilitate adhesion of tumor cells to the vascular endothelium and subsequently in the promotion of metastasis. ICAM-1 expression determines malignant potential of cancer. In this review, we will discuss the expression, function, prognosis, tumorigenesis, polymorphisms and therapeutic implications of ICAM-1 in CRC.
BibTeX
@inproceedings{qiu2022roles,
  author = {Zhiyuan Qiu and Yan Wang and Zhao Zhang and Rong Qin and Yong Peng and Weifeng Tang and Yan Xi and Guangyu Tian and Yeqing Zhang},
  title = {{Roles of intercellular cell adhesion molecule-1 (ICAM-1) in colorectal cancer: expression, functions, prognosis, tumorigenesis, polymorphisms and therapeutic implications}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.1052672},
}
Figure